-
2022-502833-25-00
5
2023-08-02
Obesity
-
2022-502234-70-00
5
2023-07-14
Chronic Obstructive Pulmonary Disease (COPD)
-
2022-501362-22-00
10
2023-04-18
Psoriatic Arthritis
-
2022-501426-38-00
4
2023-02-09
Lipoprotein Disorder
-
2024-511254-51-00
1
2023-02-09
Glaucoma
-
2024-513992-42-00
10
2022-09-13
venous thromboembolism (VTE) in patients with gastrointestinal/genitou
-
2023-505441-69-00
5
2022-05-17
refractory, advanced gastro-oesophageal cancer
-
2024-511263-28-00
6
2022-04-08
Hypercholesterolemia
-
2024-513568-24-00
5
2022-03-23
Inadequately Controlled Asthma
-
2024-512314-17-00
5
2021-11-24
Aneurysmal Subarachnoid Hemorrhage (SAH)
-
2023-505203-23-01
5
2021-07-26
Severe asthma with an eosinophilic phenotype
-
2023-510230-84-00
5
2021-05-28
Severe asthma with an eosinophilic phenotype
-
2023-507002-14-00
4
2021-05-20
treatment-naïve or relapsed/refractory chronic lymphocytic leukemia
-
2023-508259-38-00
5
2021-04-29
Adult patients with relapsed or primary refractory DLBCL
-
2024-510745-34-00
10
2020-11-11
Bullous Pemphigoid
-
2023-507846-96-00
5
2020-06-19
Type 2 Diabetes Mellitus
-
2024-514471-18-00
5
2020-05-13
Invasive Fungal Diseases in Adults undergoing Allogeneic Blood and Mar
-
2024-514007-34-00
5
2020-03-08
Children with congenital hyperinsulinism
-
2023-506715-18-00
5
2019-12-04
colon cancer stage II, rectal cancer stage II
-
2023-508022-10-00
6
2019-07-25
Rheumatoid Arthritis
-
2022-501970-20-01
5
2019-06-07
Cis-eligible Muscle-invasive bladder cancer.
-
2023-503673-38-00
5
2019-05-24
Adults at high risk of cardiovascular events without prior MI or strok
-
2024-513513-12-00
5
2019-01-06
Cholangiocarcinoma
-
2024-512158-12-00
5
2018-12-14
Bladder Cancer
Muscle-Invasive Bladder Cancer